EUDA Health (EUDA) announced that it has signed a Letter of Intent, LOI, to potentially acquire Chemokine. EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- EUDA Health Secures Global Rights for New Immune Supplement
- EUDA Health Stock Pops 14% on New Wellness Deal
- EUDA Health secures worldwide distribution rights for Chemokine supplement
- EUDA Health Holdings Secures $10 Million Convertible Note Agreement